Ark slumps after gene therapy Cerepro rejected in EU for brain cancer
This article was originally published in Scrip
Executive Summary
Ark Therapeutics' Cerepro (sitimagene ceradenovec), which could have become the first gene therapy approved in the EU, has been rejected by the CHMP for the treatment of operable high grade glioma (brain cancer), leading to a 50% fall in the company’s share price on the London Stock Exchange on December 18th. The company plans to appeal the decision immediately and expects the appeal process to take about four months.